Global Atopic Dermatitis (AD) Market Insights, Epidemiology and Forecasts to 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

According to research, the global market of Atopic Dermatitis was estimated to be USD 2.2 billion in 2016.

The prevalent population of Atopic Dermatitis was estimated to be 40.78 Million [7MM] in 2016. United States accounts for the highest AD Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Adults are largely affected with the Atopic Dermatitis. Among EU5, France has been reported to have the highest prevalent population of Atopic Dermatitis.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Atopic Dermatitis from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess underlying potential of the market.

Companies Mentioned:

  • Dermata Therapeutics
  • DS Biopharma
  • Galderma Pharma
  • GlaxoSmithKline
  • LEO Pharma
  • Menlo Therapeutics
  • Nippon Shinyaku
  • Novartis
  • Otsuka Pharmaceutical
  • Roche
  • Roivant Sciences
  • Tioga Pharmaceuticals
  • Vanda Pharmaceuticals

Key Topics Covered:

1. Report Introduction

2. Atopic Dermatitis Market Overview at a Glance

3. Disease Background and Overview

4. Epidemiology and Patient Population

5. Treatment Practices

6. Treatment Algorithm

7. Treatment Failure

8. Emerging Therapies

9. Nemolizumab: Galderma Pharma

10. Tralokinumab: LEO Pharma

11. Tradipitant: Vanda Pharmaceuticals

12. ZPL-389: Novartis

13. NST-141: Nippon Shinyaku

14. Serlopitant: Menlo Therapeutics

15. DS107: DS Biopharma

16. Asimadoline: Tioga Pharmaceuticals

17. GSK2894512: GlaxoSmithKline

18. Lebrikizumab: Roche

19. DMT210: Dermata Therapeutics

20. RVT-501: Roivant Sciences

21. OPA-15406: Otsuka Pharmaceutical

22. Current Unmet Need

23. Atopic Dermatitis: Market Analysis

24. Atopic Dermatitis: United States Market Outlook

25. Atopic Dermatitis: EU5 Market Outlook

26. Atopic Dermatitis: Japan Market Outlook

27. Market Drivers

28. Market Barriers

29. Expert Opinions

30. Views on Current Treatment Options

31. Views on Emerging Therapies

32. Appendix

33. Report Methodology

34. Capabilities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/v5rnv9/global_atopic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Dermatology, Dermatological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Dermatology, Dermatological Drugs